Logo

ICHOR Vascular Inc

To become the “1st line on the table therapy” in treating peripheral vascular occlusions by developing a “versatile” solution aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.

Not Set

One Liner

One Liner
To become the “1st line on the table therapy” in treating peripheral vascular occlusions by developing a “versatile” solution aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.

What Problem We are Solving

Problem
Peripheral Vascular Occlusions are less studied or understood relative to Stroke or Coronary disease. Yet arterial and venous disease of the lower limbs is a larger, faster growing market with significant mortality rates. Tools and techniques have not improved outcomes in ~50 years yet costs are skyrocketing. Current options lack flexibility and broad utility! 

About Us

About Us
ICHOR Vascular has developed a 7F (510k) arterial and a 14F (510K) venous percutaneous reperfusion system which offers versatility to treat a wide range of vascular occlusions (2mm – 18mm vessels) “A one size fits all system that replicates successful parameters of surgical clot removal. The technology gives physicians clinical flexibility and incorporates a health economic element that will make ICHOR a 1st line on the table therapy for physicians and hospitals.” The ICHOR System is addressing shortcomings of current therapeutic options: Non-drug therapy non-surgical therapy Avoids blood loss Avoids distal embolization Avoids scarring or valve damage Versatile to treat a wide range of Arterial & Venous occlusions Does not require capital equipment. 

Venture Highlights

Highlights
  • https://evtoday.com/articles/2022-feb/the-ichor-reperfusion-system-for-clot-removal-in-lower-extremity-vascular-disease 

Business Model

Business Model
A highly networked team surrounded with best in class service providers (proven).  NAMSA (largest medical device testing firm in the world) is a 10% owner and significant partner in the development process.  Medical Murray is our design and engineering house with significant manufacturing capabilities for both the 7F and 14F systems.  We are incredible disciplined with our capital which is a result of our partners and 30+ years of experience in R&D, Marketing, Sales, and Engineering (100% in MedTech).

Competitive Advantage

Quote
In a white-hot market with major players anxious to compete now
•Top players all above $5B market caps ($20B global market)
•High Margin, High ASP, High Volume product lines
•Strategics all support “tools in toolbox” and seeking solutions

Devices that will 100% compete with Inari and Penumbra
•Proven mechanisms of action (50+ years)
•Versatility
•Economics

A US 510(k) cleared device (7F) used in 25+ patients
•Safety & Efficacy
•Excellent IP (granted, protected)

A platform into future indications
•Pulmonary Embolism
•Dialysis

Best in class team, advisors, and partners (therapeutic experts in R&D, Sales, Marketing, and Manufacturing)

Revenue

Revenue To Date
N/A
MRR
N/A
Revenue YTD
N/A
Burn Rate
$70K

Users

Total Users
10
Total Users (Past 30 Days)
N/A
Daily Active Users
N/A
Monthly Active Users
N/A
Total Paying Users
5
MoM Growth Users
N/A
Organic Traffic %
N/A

Customer Costs

CAC
N/A
LTV
N/A
Churn
N/A
Margins
85%

Go-To Market Strategy

Business Strategy
1.  Recent 510(k) market clearance of the 14F venous solution and an expected clearance of the 7F in Q2 2024 (arterial and venous solutions).  We have conducted 25 patients with 7F to validate the bench and in vivo studies and currently using the 14F devices in the real world. 
2.  Limited Market Release with the 7F and 14F in early 2024 to perfect the messaging, validate the sales process, demonstrate repeat orders and ASPs, and begin the real-world clinical registry.
3.  Series A to support the broader US sales expansion, EU market submissions, and OUS expansion opportunities.

Competitive Analysis

Competitive Analysys
How we win?  

Versatility:  Its a better system offering flexibility to aspirate vessels, sweep vessels, snare debris, and compatible with stents, balloons, and other products often required with these patients. 
“These are versatile, broad utility devices aimed to be the Swiss Army Knife in the thrombectomy toolbox”

Positioning:  To become the “1st line on the table therapy” in treating peripheral vascular occlusions … aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.
“Let me start with ICHOR to get the embolic material or thrombus out and see what else I need to do.  I will know in 45 minutes if I am done, or this patient needs a more aggressive therapy”
Competitor Website
Boston Scientific www.bostonscientific.com
Penumbra www.penumbrainc.com
Inari Medical www.inarimedical.com

Networking

Networking
We are open to meeting up to grab a coffee, or just to chat. We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!

Share

Capital

Loading...
Name Amount
Amount Left $1,000,000.00
Amount Raised (This Round) $4,000,000.00
Amount Raise To Date $6.8M
Investment Type N/A
Type of Raise Series A

Valuation
$18M
Friends & Family
$1.3M
Preseed
$2.2M
Seed Bridge
$3.3M

TAM SAM SOM

TAM
$20B
SAM
$20B
SOM
$4.7B

Business Stage

Business Stage
Series A

Business Type

Business Types
Investor-Backed

Categories

Healthcare

One-Pager

Download
Last Updated: 09/12/22